Nurix Therapeutics, Inc. – NASDAQ:NRIX

Add to watchlist

$9.89

-9.21

-48.25%

Market closed

Open in about 12 hours

-19.77%

month

-19.77%

quarter

+96.00%

year

Market Cap	1.40B
Enterprise value	397.11M

P/E	-2.35
EV/Sales	10.28
EV/EBITDA	-2.35
Price/Sales	11.64
Price/Book	1.48
PEG ratio	0.05
EPS	-2.92

Revenue	62.30M
EBITDA	-163.98M
Income	-165.00M
Revenue Q/Q	-60.58%
Revenue Y/Y	2.24%

Profit margin	-466.93%
Oper. margin	-476.01%
Gross margin	0%
EBIT margin	-476.01%
EBITDA margin	-263.21%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nurix Therapeutics Stock Forecast

M Q Y

Last Year

$32.78

Potential upside: 231.42%

Analysts Price target
Financials & Ratios estimates

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Profit margin
Aug 2023	18.46M	-36.98M	-200.26%
Nov 2023	15.15M	-41.95M	-276.77%
Feb 2024	16.58M	-41.51M	-250.33%
May 2024	12.09M	-44.54M	-368.39%

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Debt to assets
Aug 2023	308195000	74.37M	24.13%
Nov 2023	364539000	164.04M	45%
Feb 2024	312674000	143.92M	46.03%
May 2024	511031000	140.33M	27.46%

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Cash Flow
Aug 2023	-41.13M	22.77M	1.70M
Nov 2023	21.74M	-14.37M	4.94M
Feb 2024	-41.95M	35.51M	1.62M
May 2024	-39.70M	-131.07M	237.75M

Nurix Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Employee count
Aug 2023	297
Sep 2023	297
Oct 2023	297
Nov 2023	297
Dec 2023	297
Jan 2024	297
Feb 2024	297
Mar 2024	284
Apr 2024	284
May 2024	284
Jun 2024	284
Jul 2024	284

Nurix Therapeutics
Hedge Funds Holdings Q1 2023

31.45% -56.35%

of NRIX is owned by hedge funds

72 -46

hedge funds hold NRIX stock

16.98M -25.68M

shares is hold by hedge funds

NRIX hedge funds holdings changes

Nurix Therapeutics
Insider Trading

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	5765
Feb 2024	0	6812
Apr 2024	0	4907
May 2024	0	3499
Jun 2024	0	25760
Jul 2024	0	14578
Aug 2024	0	39107
Sep 2024	0	9050
Oct 2024	0	19037
Nov 2024	0	12596
Dec 2024	0	5760

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	2 Dec 2024	RING CHRISTINE officer: Chief Le..	Employee Stock Option (right to buy)	5,760	$1.86	$10,714
Option	2 Dec 2024	RING CHRISTINE officer: Chief Le..	Common Stock	5,760	$1.86	$10,714
Sale	2 Dec 2024	RING CHRISTINE officer: Chief Le..	Common Stock	5,760	$21.73	$125,153
Option	4 Nov 2024	RING CHRISTINE officer: Chief Le..	Employee Stock Option (right to buy)	3,290	$9.57	$31,485
Option	4 Nov 2024	RING CHRISTINE officer: Chief Le..	Common Stock	3,290	$9.57	$31,485
Sale	4 Nov 2024	RING CHRISTINE officer: Chief Le..	Common Stock	3,290	$25	$82,250
Option	1 Nov 2024	RING CHRISTINE officer: Chief Le..	Employee Stock Option (right to buy)	5,760	$1.86	$10,714
Option	1 Nov 2024	RING CHRISTINE officer: Chief Le..	Common Stock	5,760	$1.86	$10,714
Sale	1 Nov 2024	RING CHRISTINE officer: Chief Le..	Common Stock	5,760	$24.28	$139,864
Sale	1 Nov 2024	VAN HOUTE HANS officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	3,546	$24.28	$86,083

NRIX insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY Filling date: 4 Feb 2020 Issue date: 12 May 2022	4 Feb 2020	12 May 2022
Application	Application BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Filling date: 5 May 2021 Issue date: 18 Nov 2021	5 May 2021	18 Nov 2021
Application	Application BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY Filling date: 3 Dec 2020 Issue date: 1 Jul 2021	3 Dec 2020	1 Jul 2021
Application	Application CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY Filling date: 23 Sep 2020 Issue date: 25 Mar 2021	23 Sep 2020	25 Mar 2021
Application	Application CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS Filling date: 23 Sep 2020 Issue date: 25 Mar 2021	23 Sep 2020	25 Mar 2021
Application	Application SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF Filling date: 26 Jun 2020 Issue date: 25 Feb 2021	26 Jun 2020	25 Feb 2021
Application	Application CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF Filling date: 15 May 2020 Issue date: 25 Feb 2021	15 May 2020	25 Feb 2021
Application	Application 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS Filling date: 9 Apr 2020 Issue date: 15 Oct 2020	9 Apr 2020	15 Oct 2020

Nurix Therapeutics
Executives

Insider	Age	Compensation
Dr. Arthur T. Sands (1962) Chief Executive Officer, Pres & Director	63	$852,770
Dr. Gwenn M. Hansen Ph.D. (1971) Chief Scientific Officer	54	$673,850
Dr. Christine Ring (1965) Gen. Counsel & Sec.	60	$548,450

Nurix Therapeutics
Latest News

Monday, 9 December 2024
18:00	Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting	globenewswire.com
Monday, 2 December 2024
07:00	Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting	globenewswire.com
Monday, 25 November 2024
07:00	Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference	globenewswire.com
Wednesday, 20 November 2024
16:00	Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia	globenewswire.com
Sunday, 17 November 2024
10:30	Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024	globenewswire.com
Thursday, 31 October 2024
07:00	Nurix Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Monday, 21 October 2024
16:00	Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit	globenewswire.com
Saturday, 19 October 2024
08:00	Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia	globenewswire.com
Wednesday, 16 October 2024
16:35	Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur	globenewswire.com
Friday, 11 October 2024
18:10	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
16:00	Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	globenewswire.com
Wednesday, 9 October 2024
07:00	Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology	globenewswire.com
Tuesday, 8 October 2024
10:58	Nurix: An Attractive Early-Stage Biotech Play	seekingalpha.com
Monday, 30 September 2024
07:00	Nurix Therapeutics Announces Presentations at Discovery on Target Conference	globenewswire.com
Friday, 6 September 2024
07:00	Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit	globenewswire.com
Wednesday, 4 September 2024
11:59	Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data	seekingalpha.com
Thursday, 29 August 2024
07:00	Nurix Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Thursday, 25 July 2024
10:56	How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%	zacks.com
Tuesday, 16 July 2024
13:05	Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice	zacks.com
Thursday, 11 July 2024
18:10	Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates	zacks.com
16:00	Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	globenewswire.com
Wednesday, 19 June 2024
06:05	Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?	zacks.com
Tuesday, 28 May 2024
07:00	Nurix Therapeutics Appoints Paula G. O'Connor, M.D.	globenewswire.com
Monday, 20 May 2024
16:00	Nurix Therapeutics Announces Board Chair Transition	globenewswire.com
11:26	Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?	zacks.com
Tuesday, 14 May 2024
10:00	Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)	globenewswire.com
Tuesday, 7 May 2024
07:00	Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference	globenewswire.com
Tuesday, 16 April 2024
18:21	Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	globenewswire.com
Thursday, 11 April 2024
23:38	Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	globenewswire.com
16:00	Nurix Therapeutics Announces Proposed Public Offering	globenewswire.com

Ideas & Opinions

Seeking Alpha 13 Jul 2025

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors
Seeking Alpha 17 Apr 2025

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
Seeking Alpha 9 Jan 2025

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Seeking Alpha 19 Jun 2024

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Seeking Alpha 22 Jan 2024

Nurix Therapeutics: A Unique Approach To BTK Targeting
Seeking Alpha 26 Jun 2023

Nurix: Still Promising, But No New Development Except Gilead Licensing Asset
Seeking Alpha 20 Mar 2023

Nurix: Promising Early Data From This Protein Degrader Company
Seeking Alpha 27 Oct 2022

Nurix: Down, But Not Out
Seeking Alpha 21 Nov 2021

Nurix: Advancing Targeted Protein Modulation Therapies
Seeking Alpha 10 Jun 2021

Aptose: Cancer Trial Catalyst Ahead At EHA21

Frequently Asked Questions (FAQ)

What's the price of Nurix Therapeutics stock today?

One share of Nurix Therapeutics stock can currently be purchased for approximately $9.89.
When is Nurix Therapeutics's next earnings date?

Unfortunately, Nurix Therapeutics's (NRIX) next earnings date is currently unknown.
Does Nurix Therapeutics pay dividends?

No, Nurix Therapeutics does not pay dividends.
How much money does Nurix Therapeutics make?

Nurix Therapeutics has a market capitalization of 1.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.31% to 76.99M US dollars.
What is Nurix Therapeutics's stock symbol?

Nurix Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NRIX".
What is Nurix Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nurix Therapeutics?

Shares of Nurix Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Nurix Therapeutics's key executives?
Nurix Therapeutics's management team includes the following people:
- Dr. Arthur T. Sands Chief Executive Officer, Pres & Director(age: 63, pay: $852,770)
- Dr. Gwenn M. Hansen Ph.D. Chief Scientific Officer(age: 54, pay: $673,850)
- Dr. Christine Ring Gen. Counsel & Sec.(age: 60, pay: $548,450)
How many employees does Nurix Therapeutics have?

As Jul 2024, Nurix Therapeutics employs 284 workers.
When Nurix Therapeutics went public?

Nurix Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.
What is Nurix Therapeutics's official website?

The official website for Nurix Therapeutics is nurixtx.com.
Where are Nurix Therapeutics's headquarters?

Nurix Therapeutics is headquartered at 1700 Owens Street, San Francisco, CA.
How can i contact Nurix Therapeutics?

Nurix Therapeutics's mailing address is 1700 Owens Street, San Francisco, CA and company can be reached via phone at +41 56605320.
What is Nurix Therapeutics stock forecast & price target?

Based on 8 Wall Street analysts` predicted price targets for Nurix Therapeutics in the last 12 months, the avarage price target is $32.78. The average price target represents a 231.42% change from the last price of $9.89.

Nurix Therapeutics, Inc.

nurixtx.com

Exchange:

NASDAQ

Full time employees:

284

Industry:

Biotechnology

Sector:

Healthcare

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

+41 56605320

1700 Owens Street
San Francisco, CA 94158

CIK: 0001549595
ISIN: US67080M1036
CUSIP: 67080M103